Case reports have similarly described Crohn’s disease patients developing longitudinally extensive TM while on adalimumab, supporting the possibility that TNF-α blockade may unmask or precipitate demyelinating disease in susceptible individuals [1,3,8]. This evidence concerns the gene TNF and demyelinating disease.